3-羟基环己基氨基甲酸叔丁酯 | 610302-03-9

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-羟基环己基氨基甲酸叔丁酯
• 中文别名: N-Boc-3-氨基环己醇；3-(Boc-氨基)环己醇；N-BOC-3-氨基环己醇
• 英文名称: tert-butyl (3-hydroxycyclohexyl)carbamate
• 英文别名: tert-butyl N-(3-hydroxycyclohexyl)carbamate
• CAS: 610302-03-9
• 化学式: C₁₁H₂₁NO₃
• 分子量: 215.293
• InChiKey: IUKYKMHCKDLTJC-UHFFFAOYSA-N

物化性质

• 沸点：
  337.7±31.0 °C(Predicted)
• 密度：
  1.06

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : (3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl
ester
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 610302-03-9
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 1), H410
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn, N Harmful, Dangerous for the R22, R50/53
environment
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statement(s)
P273 Avoid release to the environment.
P501 Dispose of contents/ container to an approved waste disposal plant.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C11H21NO3
Molecular Weight : 215,29 g/mol
CAS-No. : 610302-03-9
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
(3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester
Acute Tox. 4; Aquatic Acute 1; -
Aquatic Chronic 1; H302,
H410
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
(3-Hydroxy-cyclohexyl)-carbamic acid tert-butyl ester
Xn, N, R22 - R50/53 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 1,878
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
Very toxic to aquatic life with long lasting effects.
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 3077 IMDG: 3077 IATA: 3077
UN proper shipping name
ADR/RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. ((3-Hydroxy-cyclohexyl)-
carbamic acid tert-butyl ester)
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. ((3-Hydroxy-cyclohexyl)-
carbamic acid tert-butyl ester)
IATA: Environmentally hazardous substance, solid, n.o.s. ((3-Hydroxy-cyclohexyl)-carbamic acid
tert-butyl ester)
Transport hazard class(es)
ADR/RID: 9 IMDG: 9 IATA: 9
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: yes
Special precautions for user
Further information
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and combination
packagings containing inner packagings with Dangerous Goods > 5L for liquids or > 5kg for solids.

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-羟基环己基氨基甲酸叔丁酯 在 氢溴酸 、 potassium carbonate 、 三乙胺 、 lithium bromide 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 2-thia-4-azabicyclo[3.3.1]nonane-3-thione
  参考文献：
  名称：

  Synthesis of 2-thia-4-azabicyclo[3.3.1]non-3-en-3-amine – bridged nitric oxide synthase inhibitor with enhanced lipophilicity

  摘要：

  2-Thia-4-azabicyclo[3.3.1]non-3-en-3-amine was synthesized as a lipophilic analogue of NO-synthase inhibitor 2-amino-5,6-dihydro-4H-1,3-thiazine and found to be a potent inhibitor of inducible NO-synthase in vitro. The crystal structure of the key intermediate 2-thia-4-azabicyclo[3.3.1]nonane-3-thione (obtained by cyclization of trans-3-bromocyclohexylamine with carbon disulfide) was determined by X-ray analysis.

  DOI：

  10.1016/j.mencom.2013.03.006
• 作为产物：
  描述：

  3-N-叔丁氧羰基氨基环己酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 14.0h， 以100%的产率得到3-羟基环己基氨基甲酸叔丁酯
  参考文献：
  名称：

  POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

  摘要：

  本文描述了一种新型的多氟取代吡唑嘧啶化合物或其盐。这些化合物是布鲁顿酪氨酸激酶（BTK）抑制剂。这些化合物可能具有更好的BTK抑制选择性和药代动力学特性。本文披露了这些化合物的合成方法。本文还披露了多氟取代苯甲酮和取代苯氧基苯的新型合成方法。还披露了包括上述BTK抑制剂的药物组合物。本发明还涉及包含上述化合物作为活性成分的药物配方。本发明还包括通过给予BTK抑制剂及其配方来治疗和抑制自身免疫疾病、过敏性疾病、炎症性疾病和癌症的治疗方法。

  公开号：

  US20160200730A1

文献信息

• BTK INHIBITOR
  申请人：Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

  公开号：US20170313683A1

  公开（公告）日：2017-11-02

  Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

  提供了一系列的BTK抑制剂，特别公开了一种由公式(I)、(II)、(III)或(IV)表示的化合物、药用可接受的盐、互变异构体或前药。
• [EN] ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS<br/>[FR] DÉRIVÉS D'ISOXAZOLE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES ET DE TROUBLES PULMONAIRES
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2017040606A1

  公开（公告）日：2017-03-09

  The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

  本公开涉及使用公开的化合物治疗慢性阻塞性肺疾病（COPD）、支气管炎和/或哮喘等疾病的方法，可选择性地与一个或多个额外活性剂一起使用。考虑的方法包括口服或吸入给患者一个或多个公开的化合物。
• SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20150175557A1

  公开（公告）日：2015-06-25

  Provided herein are diaminopyrimidyl Compounds having the following structures: wherein X, L, R 1 , and R 2 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidyl Compound, and methods for treating or preventing PKC-theta-mediated disorders, or a condition treatable or preventable by inhibition of a kinase, for example, PKC-theta.

  本文提供具有以下结构的二氨基嘧啶化合物： 其中X、L、R1和R2如本文所定义，包含有效量二氨基嘧啶化合物的组合物，以及用于治疗或预防PKC-theta介导的疾病或通过抑制激酶（例如PKC-theta）可治疗或预防的疾病的方法。
• [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044770A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  具有式（IX）的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义，并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病，包括癌症的方法。
• [EN] ARYL SUBSTITUTED PYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION<br/>[FR] PYRIMIDINES À SUBSTITUTION ARYLE À UTILISER DANS UNE INFECTION PAR LE VIRUS DE LA GRIPPE
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：WO2017125506A1

  公开（公告）日：2017-07-27

  The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

  这项发明涉及具有式（I）结构的化合物，可用于治疗或预防流感感染。